Coibamide A kills cancer cells through inhibiting autophagy
Wenli Shi,Danyi Lu,Chunlei Wu,Meiqing Li,Zhihao Ding,Yanyan Li,Binghua Chen,Xian Lin,Wu Su,Ximing Shao,Zhihui Xia,Lijing Fang,Ke Liu,Hongchang Li
DOI: https://doi.org/10.1016/j.bbrc.2021.01.112
IF: 3.1
2021-04-01
Biochemical and Biophysical Research Communications
Abstract:<p>Natural products are useful tools for biological mechanism research and drug discovery. Due to the excellent tumor cell growth inhibitory profile and sub-nanomolar potency, Coibamide A (CA), an N-methyl-stabilized depsipeptide isolated from marine cyanobacterium, has been considered as a promising lead compound for cancer treatment. However, the molecular anti-cancer mechanism of the action of CA remains unclear. Here, we showed that CA treatment induced caspase-independent cell death in breast cancer cells. CA treatment also led to severe lysosome defects, which was ascribed to the impaired glycosylation of lysosome membrane protein LAMP1 and LAMP2. As a consequence, the autophagosome-lysosome fusion was blocked upon CA treatment. In addition, we presented evidence that this autophagy defect partially contributed to the CA treatment-induced tumor cell death. Together, our work uncovers a novel mechanism underlying the anti-cancer action of CA, which will promote its further application for cancer therapy.</p>
biochemistry & molecular biology,biophysics